Ball Titus B. sold $47K of ONC

BeOne Medicines reported Q3 2026 earnings, highlighting Brukinsa's U.S. sales exceeding $1 billion. Management discussed competitive threats, R&D investments, and clinical trial updates. Operating margins are expected to expand by over 10% in 2026, with future growth balanced against investment. The company is expanding its CDK4 inhibitor Phase III study and partnering with Revolution Medicines on precision oncology initiatives.

Jefferies raised its price target for BeOne Medicines (ONC) to $470 from $410, citing strong quarterly results and raised guidance. The stock trades near its 52-week high at $387.27. The company reported $1.7B in Q2 2026 revenue, up 29% YoY, and raised its full-year 2026 revenue guidance to $6.6B-$6.8B. Analysts highlight robust margins, revenue growth, and a solid pipeline.

BeOne Medicines DRC (ONC) reported Q3 EPS of $4.55, exceeding estimates by $2.66, with revenue of $1.89B, topping expectations of $1.75B. The stock is up 8.47% over 3 months and 19.10% over 12 months. InvestingPro rates its financial health as 'great performance'.

BeOne Medicines reported Q3 2026 revenue of $1.89 billion, up 34% YoY, with GAAP earnings of $3.28 per ADS. The company raised its full-year revenue guidance to $6.9B-$7.0B. Key products BRUKINSA and TEVIMBRA saw regulatory progress, and the company announced new collaborations and partnerships.

BeOne Medicines Ltd. (ONC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 BeOne Medicines Announces Third Quarter 2026 Financial Results and Business Updates • Total global revenues of $1.9 billion for the third quarter, an increase of 34% from the prior year • BRUKINSA (zanubrutinib) global revenues of $1.4 billion for the third quarter,

BeOne Medicines (ONC) announced FDA Priority Review for BRUKINSA (zanubrutinib) plus rituximab in first-line mantle cell lymphoma, based on Phase 3 MANGROVE trial results showing 43% reduced risk of disease progression or death. If approved, it would be the first chemotherapy-free regimen for this indication. The company is also seeking approvals in Europe and China. BRUKINSA is already approved for other B-cell malignancies.